NPS Pharmaceuticals Inc (NPSP.OQ)

NPSP.OQ on NASDAQ Stock Exchange Global Select Market

36.04USD
19 Dec 2014
Price Change (% chg)

$-0.57 (-1.56%)
Prev Close
$36.61
Open
$36.56
Day's High
$36.76
Day's Low
$35.68
Volume
1,064,466
Avg. Vol
591,810
52-wk High
$39.67
52-wk Low
$22.12

NPSP.OQ

Chart for NPSP.OQ

About

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food... (more)

Overall

Beta: 0.81
Market Cap (Mil.): $3,850.50
Shares Outstanding (Mil.): 106.84
Dividend: --
Yield (%): --

Financials

  NPSP.OQ Industry Sector
P/E (TTM): 3,586.07 179.07 38.47
EPS (TTM): 0.01 -- --
ROI: 0.44 -0.72 18.25
ROE: 0.93 -1.88 19.13
Search Stocks

Shire considering bid for NPS Pharmaceuticals: Bloomberg

- Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

Deals of the day- Mergers and acquisitions

(Adds Shire, Carrefour, Clessidra, CMVM, Snam, Eni, Lala, Lucchini and KGHM)

17 Dec 2014

Shire considering bid for NPS Pharmaceuticals: Bloomberg

- Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

Shire considering bid for NPS Pharmaceuticals - Bloomberg

Dec 17 - Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar with the matter.

17 Dec 2014

FDA extends review date for NPS Pharma hormone replacement therapy

Oct 23 - NPS Pharmaceuticals Inc said the U.S. Food and Drug Administration had extended the review date for its hormone replacement therapy by three months to provide time for a full review of a "major amendment."

23 Oct 2014

U.S. FDA panel recommends approval of NPS hormone replacement drug

- A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted 8-5 to recommend approval for Natpara, a hormone replacement therapy developed by NPS Pharmaceuticals Inc.

12 Sep 2014

U.S. FDA panel recommends approval of NPS hormone replacement drug

Sept 12 - A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted 8-5 to recommend approval for Natpara, a hormone replacement therapy developed by NPS Pharmaceuticals Inc.

12 Sep 2014

FDA staff: NPS drug effective; no significant safety imbalance

WASHINGTON - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials, though data from one trial site was excluded due to manufacturing violations, according to a preliminary review by the U.S. Food and Drug Administration.

10 Sep 2014

FDA staff: NPS drug effective; no significant safety imbalance

WASHINGTON, Sept 10 - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials, though data from one trial site was excluded due to manufacturing violations, according to a preliminary review by the U.S. Food and Drug Administration.

10 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks